Rivals chase Bristol-Myers in cancer immunotherapy drug race
February 26, 2016 at 09:08 AM EST
LONDON, Feb 26 (Reuters) - Bristol-Myers Squibb has pulled ahead in the race to dominate the hot new cancer immunotherapy market but Merck & Co, Roche and AstraZeneca still have important opportunities to close the gap.
